Previous studies have demonstrated that treatment with Sivelestat or administration of SERPINA1 and Elafin (human NE inhibitors) attenuates disease.42–44 In contrast to these studies, we have used a natural murine NE inhibitor, SerpinA3N, to target NE in a physiological model of infection-induced colitis. This evidence concerns the gene SERPINA1 and infection.